These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37028605)

  • 1. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
    Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
    Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
    Jadhav H; Augustijns P; Tannergren C
    Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models.
    Sjögren E; Thörn H; Tannergren C
    Mol Pharm; 2016 Jun; 13(6):1763-78. PubMed ID: 26926043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
    Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
    J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.
    Subhani S; Kim C; Muniz P; Rodriguez M; van Os S; Suarez E; Cristofoletti R; Schmidt S; Vozmediano V
    Eur J Pharm Biopharm; 2022 Jul; 176():87-94. PubMed ID: 35598768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.
    Wu D; Tsekouras AA; Macheras P; Kesisoglou F
    Pharm Res; 2023 Feb; 40(2):419-429. PubMed ID: 36050545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
    Darwich AS; Margolskee A; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():626-642. PubMed ID: 27693299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
    Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
    Melillo N; Aarons L; Magni P; Darwich AS
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
    Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
    J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.